{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cunningham A"],"funding":["BLRD VA","NCATS NIH HHS","NIDDK NIH HHS","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["1376587"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11345262"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6"],"pubmed_abstract":["Gadolinium-based contrast agents are increasingly used in clinical practice. While these pharmaceuticals are verified causal agents in nephrogenic systemic fibrosis, there is a growing body of literature supporting their role as causal agents in symptoms associated with gadolinium exposure after intravenous use and encephalopathy following intrathecal administration. Gadolinium-based contrast agents are multidentate organic ligands that strongly bind the metal ion to reduce the toxicity of the metal. The notion that cationic gadolinium dissociates from these chelates and causes the disease is prevalent among patients and providers. We hypothesize that non-ligand-bound (soluble) gadolinium will be exceedingly low in patients. Soluble, ionic gadolinium is not likely to be the initial step in"],"journal":["Frontiers in toxicology"],"pubmed_title":["The safety of magnetic resonance imaging contrast agents."],"pmcid":["PMC11345262"],"funding_grant_id":["P20 GM121176","I01 BX001958","P30 CA118100","UL1 TR001449","R01 DK102085"],"pubmed_authors":["Yang J","Dokladny K","Saenz-Trevizo A","Wagner B","DeAguero J","Escobar GP","Cunningham A","Hong E","Krawchuck J","Howard T","Henderson I","Watt J","Kirk M","Brearley A"],"additional_accession":[]},"is_claimable":false,"name":"The safety of magnetic resonance imaging contrast agents.","description":"Gadolinium-based contrast agents are increasingly used in clinical practice. While these pharmaceuticals are verified causal agents in nephrogenic systemic fibrosis, there is a growing body of literature supporting their role as causal agents in symptoms associated with gadolinium exposure after intravenous use and encephalopathy following intrathecal administration. Gadolinium-based contrast agents are multidentate organic ligands that strongly bind the metal ion to reduce the toxicity of the metal. The notion that cationic gadolinium dissociates from these chelates and causes the disease is prevalent among patients and providers. We hypothesize that non-ligand-bound (soluble) gadolinium will be exceedingly low in patients. Soluble, ionic gadolinium is not likely to be the initial step in","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-04-30T00:02:29.728Z","creation":"2025-04-07T04:19:30.712Z"},"accession":"S-EPMC11345262","cross_references":{"pubmed":["39188505"],"doi":["10.3389/ftox.2024.1376587"]}}